Abstracts tagged "DMARDs"

Abstract Number: 1820 • 2017 ACR/ARHP Annual Meeting
Sustained Effectiveness after Remission Induction with Methotrexate and Step-Down Glucocorticoids in Patients with Early Rheumatoid Arthritis Following a Treat-to-Target Strategy after 2 Years
Veerle Stouten¹, Johan Joly², Diederik De Cock¹, Sofia Pazmino¹, Kristien Van der Elst^2,3, René Westhovens^1,2 and Patrick Verschueren^1,2, ¹KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium, ²University Hospitals Leuven on behalf of the CareRA Study Group, Leuven, Belgium, ³KU Leuven, Department of Public Health and Primary Care, Skeletal Biology and Engineering Research Center, Leuven, Belgium
Background/Purpose: Remission induction with methotrexate (MTX) and a moderate-dose, step-down scheme of Glucocorticoids (GC), (COBRA Slim strategy), showed equally high remission rates at year 1…
Abstract Number: 989 • 2017 ACR/ARHP Annual Meeting
Impact of DMARD Treatment on Risk of Repeat Cardiovascular Events Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis
Jeffrey A. Sparks¹, Tamara Lesperance², Neil A. Accortt³ and Daniel H. Solomon⁴, ¹Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²DOCS Global, Inc., North Wales, PA, ³Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Chronic inflammatory diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and psoriasis (PsO) increase the risk of cardiovascular (CV) disease. However, it is…
Abstract Number: 1904 • 2017 ACR/ARHP Annual Meeting
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of Upadacitinib (ABT-494), a Selective JAK-1 Inhibitor, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Conventional Synthetic Dmards
Gerd R. Burmester¹, Joel Kremer², Filip van Den Bosch³, Yihan Li⁴, Yijie Zhou⁴, Ahmed A. Othman⁵, Aileen L. Pangan⁴ and Heidi S. Camp⁵, ¹Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ²Albany Medical College, Albany, NY, ³Rheumatology, Ghent University Hospital, Gent, Belgium, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie, North Chicago, IL
Background/Purpose: Upadacitinib (UPA) is an oral, selective JAK-1 inhibitor in development for the treatment of patients (pts) with moderate to severe rheumatoid arthritis (RA) and…
Abstract Number: 130 • 2017 ACR/ARHP Annual Meeting
Availability of Clinical Measures for Patients with Rheumatoid Arthritis in Integrated Delivery Networks Who Receive a Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drug: A Real-World Analysis of an Electronic Health Records Database
Benjamin Chastek¹, Chieh-I Chen², Toshio Kimura², Jonathan Fay², Stephanie Korrer³ and Stefano Fiore⁴, ¹Optum, Eden Prairie, MN, ²Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Health Economics and Outcomes Research, Optum, Eden Prairie, MN, ⁴Clinical Science, Sanofi Genzyme, Bridgewater, NJ
Background/Purpose: In patients with rheumatoid arthritis (RA), ACR treatment guidelines recommend treating to targets based on quantitative endpoints, with modification of therapy as needed to…
Abstract Number: 1033 • 2017 ACR/ARHP Annual Meeting
Burden of Illness in Patients with RA and Anti-Cyclic Citrullinated Peptide Positivity
ML Paudel¹, JP Swindle¹, J McPheeters¹, R Szymialis² and K Price², ¹Optum, Inc., Eden Prairie, MN, ²Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: RA is often treated with a biologic DMARD (bDMARD), such as abatacept (ABA) or a TNF inhibitor (TNFi). Real-world data on how economic outcomes…
Abstract Number: 1962 • 2017 ACR/ARHP Annual Meeting
Rates of Malignancy Associated with Anti-TNF Agents and Subsequent Biologic Use after Malignancy Using U.S. SEER Registry Data
Huifeng Yun¹, Fenglong Xie², Shuo Yang², Lang Chen¹ and Jeffrey R. Curtis³, ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Biologic disease-modifying anti-rheumatic drugs (DMARDs) have been widely used for treatment of rheumatoid arthritis (RA) in United States. However, it is not clear whether…
Abstract Number: 139 • 2017 ACR/ARHP Annual Meeting
No Effect of Tumor Necrosis Factor-a Inhibitors on Renal Function in Patients with Rheumatoid Arthritis from Kobio Registry from 2012 to 2016
Seong-Kyu Kim¹, Jung-Yoon Choe², Sung-Hoon Park³ and Hwajeong Lee², ¹Rheumatology, Catholic University of Daegu School of Medicine, Daegu, Korea, Republic of (South), ²Catholic University of Daegu School of Medicine, Daegu, Korea, Republic of (South), ³Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea, Republic of (South)
Background/Purpose: Renal disease is prevalent in patients with rheumatoid arthritis (RA), although the precise prevalence of RA has not been determined. Increased mortality in patients…
Abstract Number: 1036 • 2017 ACR/ARHP Annual Meeting
Blood Glucose Changes Surrounding Initiation of Tumor-Necrosis Factor Inhibitors and Conventional Disease-Modifying Anti-Rheumatic Drugs in Veterans with Rheumatoid Arthritis
Patrick R. Wood¹, Evan Manning², Joshua Baker³, Grant Cannon⁴, Lisa Davis⁵, Bryant R. England⁶, Ted R. Mikuls⁷ and Liron Caplan⁸, ¹Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²University of Colorado School of Medicine, Aurora, CO, ³Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁴Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁵Div of Rheumatology, Denver Health, Denver, CO, ⁶Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁷Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁸Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: There is evidence linking activation of the innate immune system and insulin resistance. Perturbations in glucose homeostasis upon initiation of tumor-necrosis factor inhibitors (TNFis)…
Abstract Number: 2095 • 2017 ACR/ARHP Annual Meeting
Traditional Disease Modifying Anti-Rheumatic Drugs (tDMARDs), Hydroxychloroquine (HCQ) and/or Sulfasalazine (SSZ), Are Rapidly Effective in Immune Checkpoint Inhibitors-Induced Inflammatory Arthritis
Jessie Alperin¹, Jeffrey Sarazin², Leslie Fecher³, Christopher Lao³, Seetha Monrad⁴, David Fox¹ and Elena Schiopu⁵, ¹University of Michigan Medical System, Ann Arbor, MI, ²Rheumatology, University of Michigan Medical System, Ann Arbor, MI, ³Oncology, University of Michigan Medical System, Ann Arbor, MI, ⁴Internal Medicine/Rheumatology, University of Michigan Medical System, Ann Arbor, MI, ⁵Internal Medicine, University of Michigan Medical System, Ann Arbor, MI
Background/Purpose: Immune checkpoint inhibitor (ICI) therapy is widely used in the treatment of metastatic melanoma and non-small cell lung cancer and it is under investigation…
Abstract Number: 206 • 2017 ACR/ARHP Annual Meeting
Real World IGRA Testing in Rheumatology Practice
Paul DeMarco^1,2, Megan Bishop³, Ashling Smith⁴, Herbert S. B. Baraf^1,5, Andrew Gregory DeMarco⁶, Temitope Ademola⁷, Deborah Contreras⁸, Adalisa Enriquez RMA¹, Lisa Klein¹, Kayra Perez¹, Sandra Ventura¹, Janice Whyte-Whitworth¹, Vince Calhoun¹, Theresa Bass Goldman¹ and Alan K Matsumoto^1,9, ¹The Center for Rheumatology and Bone Research, Wheaton, MD, ²Division of Rheumatology, Department of Medicine, Georgetown University School of Medicine, Washington, DC, ³Clinical Trials, The Center for Rheumatology and Bone Research, Wheaton, MD, ⁴2730 University Blvd West, Suite 306, The Center for Rheumatology and Bone Research, Wheaton, MD, ⁵Department of Medicine, George Washington University School of Medicine, Washington, DC, ⁶Department of Biochemistry and Molecular Cellular Biology, Georgetown University Department of Biochemistry and Molecular Cellular Biology, Washington, DC, ⁷The Center for Rheumatology and Bone Research, Washington, DC, ⁸2730 University Boulevard West, Suite 306, The Center for Rheumatology and Bone Research, Wheaton, MD, ⁹Department of Medicine, Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Mycobacterium tuberculosis (MTb) screening is routine for clinical trial protocols, & authorization for immunomodulators use by health insurances. Real world data is needed to…
Abstract Number: 1044 • 2017 ACR/ARHP Annual Meeting
Medical Care Costs Associated with Rheumatoid Arthritis in the US: A Meta-Analysis
Andrew Hresko¹, Tzu-Chieh Lin² and Daniel H. Solomon³, ¹Tufts Medical School, Boston, MA, ²Health Outcomes, Amgen, Thousand Oaks, CA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is a morbid, mortal, and costly condition without a cure. Treatments for RA have expanded over the last two decades…
Abstract Number: 2098 • 2017 ACR/ARHP Annual Meeting
Systemic Treatment for ACUTE Anterior Uveitis ( SYNTHETIC AND BIOLOGIC DISEASE-MODIFYINGANTIRHEUMATIC DRUGS) : A Systematic Literature Review
Alejandro Gómez-Gómez¹, Estibaliz Loza², Maria P Rosario³, Gerard Espinosa⁴, Jose M Ruiz de Morales⁵, Jose M Herreras⁶, Santiago Muñoz⁷ and Miguel Cordero-Coma⁸, ¹Hospital Universitario Infanta Sofía, Madrid, Spain, ²Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, ³Instituto de Salud Musculoesquelética, Madrid, Spain, ⁴Autoimmune Diseases Department. Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Complejo Asistencial Universitario de León, León, Spain, ⁶Ophthalmology, Hospital Universitario, IOBA, Valladolid, Spain, ⁷Rheumatology, Hospital Infanta Sofia, Madrid, Spain, ⁸Ophthalmology, Hospital de León. Spain, León, Spain
Background/Purpose: Acute anterior uveitis (AAU) is the most common form of uveitis. One third of AAU patients may present recurrences, some requiring systemic disease-modifying antirheumatic…
Abstract Number: 355 • 2017 ACR/ARHP Annual Meeting
Perceptions and Outcomes of Pregnancy and Lactation in Patients with Rheumatic Diseases
Brooke Mills¹, Kathryn H. Dao², Kristen Tecson², Emily Fishman³, Rachel Tate² and John J. Cush², ¹Internal Medicine, Baylor University Medical Center, Dallas, TX, ²Baylor Research Institute, Dallas, TX, ³Texas A&M HSC College of Medicine, Dallas, TX
Background/Purpose: Once diagnosed with a rheumatic disease, women often defer or avoid pregnancy or lactation, fearing adverse outcomes for their offspring or for themselves. Scant…
Abstract Number: 1100 • 2017 ACR/ARHP Annual Meeting
Communication between Inpatient and Outpatient Specialty Clinicians: Developing a Better Understanding of Patients with Rheumatoid Arthritis Who Are Admitted to the Hospital
Abraham Tacang¹, Christina Downey², Alfred Denio¹, Eric Newman³ and Lisa L. Schroeder⁴, ¹Rheumatology, Geisinger Medical Center, Danville, PA, ²Geisinger Medical Center, Danville, PA, ³Department of Rheumatology, Geisinger Medical Center, Danville, PA, ⁴Rheumatology, Geisinger Health System, Danville, PA
Background/Purpose: Effective communication is essential in caring for medically complex patients with rheumatoid arthritis (RA). Communication between clinicians becomes even more crucial when a patient…
Abstract Number: 2290 • 2017 ACR/ARHP Annual Meeting
Comparing Effectiveness of Early Initiation of Biologic Treatment for Newly Diagnosed Juvenile Idiopathic Arthritis Using a Novel Statistics Causal Inference Method Applied to Observational Data
Bin Huang¹, Esi Morgan², Chen Chen², Jinzhong Liu², Michelle Adams², Timothy Beukelman³, Hermine I. Brunner⁴ and Daniel J Lovell⁵, ¹Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵PRCSG, Cincinnati, OH
Background/Purpose: We compare the effectiveness of two approaches to treat Juvenile idiopathic arthritis (JIA): early combination of biologic and non-biologic disease modifying anti rheumatic drugs…

« Previous Page
1
…
7
8
9
10
11
…
24
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].